Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.

作者: Matthias Stehr , Ayssar A Elamin , Mahavir Singh

DOI: 10.1586/14787210.2015.1021784

关键词: NicotinamidaseBiologyEnzymePncANAD+ kinasePharmacologyMycobacterium tuberculosisPyrazinamidePyrazinoic acidEfflux

摘要: Pyrazinamide (PZA) is still one of the key drugs used in current therapeutic regimens for tuberculosis (TB). Despite its importance TB therapy, mode action PZA remains unknown. has to be converted active form pyrazinoic acid (POA) by nicotinamidase PncA and then excreted an unknown efflux pump. At acidic conditions, POA protonated HPOA reabsorbed into cell where it causes cellular damage. For a long time, been thought that PZA/POA no defined target action, but recent studies have shown both several different targets interfering with diverse biochemical pathways, especially NAD(+) energy metabolism. resistance seems depend not only on defective pyrazinamidase also rather result interplay many enzyme transport mechanisms.

参考文章(131)
Andrei L. Osterman, Tadhg P. Begley, A subsystems-based approach to the identification of drug targets in bacterial pathogens Progress in drug research. ,vol. 64, pp. 131- 170 ,(2007) , 10.1007/978-3-7643-7567-6_6
Ying Zhang, D. Mitchison, The curious characteristics of pyrazinamide: a review. International Journal of Tuberculosis and Lung Disease. ,vol. 7, pp. 6- 21 ,(2003)
P Kiepiela, K S Bishop, D F York, A N Smith, L Blumberg, L Roux, A P Trollip, Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. International Journal of Tuberculosis and Lung Disease. ,vol. 5, pp. 952- 957 ,(2001)
Erika Bruck, National Committee for Clinical Laboratory Standards. Pediatrics. ,vol. 65, pp. 187- 188 ,(1980)
Oren Zimhony, Jeffery S. Cox, John T. Welch, Catherine Vilchèze, William R. Jacobs, Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis Nature Medicine. ,vol. 6, pp. 1043- 1047 ,(2000) , 10.1038/79558
YING ZHANG, ZHONGHE SUN, SALLIE PERMAR, Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide Journal of Medical Microbiology. ,vol. 51, pp. 42- 49 ,(2002) , 10.1099/0022-1317-51-1-42
Mark Herbert, Elizabeta Sauer, Graeme Smethurst, Anita Kraiβ, Anna-Karina Hilpert, Joachim Reidl, Nicotinamide Ribosyl Uptake Mutants in Haemophilus influenzae Infection and Immunity. ,vol. 71, pp. 5398- 5401 ,(2003) , 10.1128/IAI.71.9.5398-5401.2003
D. A. Mitchison, Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 Months The American review of respiratory disease. ,vol. 147, pp. 1062- 1063 ,(1993) , 10.1164/AJRCCM/147.4.1062
Qiang Huang, Zhi-Fei Chen, Yuan-Yuan Li, Ying Zhang, Yi Ren, Zhijun Fu, Shun-Qing Xu, Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. Chemotherapy. ,vol. 53, pp. 338- 343 ,(2007) , 10.1159/000107723